SARASOTA, Fla., Feb. 2 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: DNAP - News) of Sarasota, FL (the "Company") announces today that the Company and Senecio Software Inc. have been awarded a highly competitive Small Business Initiative Research (SBIR) grant by the National Institutes of Health (NIH).

The principle objective of the co-authored grant application is to create software systems that will expand DNAPrint's technology reach to institutional, government and academic markets.

Recent federal directives require the use of multiracial classification on official forms and surveys and call for the Government to do a better job of recognizing diversity in ancestral origins. However, demographic research on race is becoming increasingly difficult given its multiple measures and the growing complexity in defining race.

As the first to enable an objective and quantitative measurement of continental and/or ethnogeographic ancestry admixture, DNAPrint's innovative genetic testing technology (ANCESTRYbyDNA(TM) 2.5, DNAWitness(TM) 2.5, EURO-DNA(TM) 1.0, EURO-Witness(TM) 1.0) represents a logical, scientific and convenient proxy measure for institutional, government and academic researchers.

Target markets for the software system to be developed in this grant project include government and academic demographers, social scientists and policy makers.

Customers can learn more about DNAPrint's tests for the inference of ancestry admixture at http://www.ancestrybydna.com.

About DNAPrint genomics, Inc

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com .

About Senecio Software

Founded in 1992, Senecio Software Inc. is a privately held company based in Bowling Green, Ohio. The company specializes in the design and production of advanced, multi-tier, web-based systems used in the collection and analysis of social, health, market research, and demographic data. Given the rise in Internet-based commerce and the demand for online information processing solutions, Senecio's corporate strategy has increasingly focused on the development of customized data-gathering tools used by professional survey researchers, scientists, and market analysts. Along with designing multi-tier, web-based survey software, Senecio is developing unique data gathering tools involving remote sensing and wireless communication. Senecio Software has been the recipient of numerous research grants from the U.S. government's National Institutes of Health. Additional information about the company, its products, partnerships and research agenda can be found at http://www.senecio.com.

Funding for this research is provided through the Department of Health and Human Services Small Business Innovation Research Program, National Institutes of Health. Grant Number: 1 R43 AGO25768-01A1 - National Institute on Aging.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint Genomics, Inc.
CEO/President
(941) 366-3400